Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone (Ongentys) in Chinese patients with Parkinson's disease and end-of-dose wearing-off
CTR20230270Phase 3Completed
- Sponsor
- BIAL
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Started Feb 2023; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20230270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230270.